Literature DB >> 20843739

Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease.

Barbara C Kahl1.   

Abstract

One of the first pathogens which can be isolated from the airways of cystic fibrosis (CF) patients is Staphylococcus aureus, which often persists in this hostile environment for many months or even years. The increase in infections due to the methicillin-resistant S. aureus (MRSA) worldwide and even more the emergence of community-acquired MRSA, which differ from nosocomial MRSA by lack of multiresistance and carriage of a phage-encoded toxin, Panton-Valentine leukocidin, attracts new attention to the epidemiology, pathogenesis, and impact of S. aureus in the background of CF. In this review, recent data and studies will be reported and discussed to give an overview of the latest research.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20843739     DOI: 10.1016/j.ijmm.2010.08.002

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  22 in total

1.  Shining new light on newborn screening of cystic fibrosis in the province of Quebec.

Authors:  Léticia Khendek
Journal:  Can J Public Health       Date:  2017-09-14

2.  Staphylococcus aureus Survives in Cystic Fibrosis Macrophages, Forming a Reservoir for Chronic Pneumonia.

Authors:  Cao Li; Yuqing Wu; Andrea Riehle; Jie Ma; Markus Kamler; Erich Gulbins; Heike Grassmé
Journal:  Infect Immun       Date:  2017-04-21       Impact factor: 3.441

3.  Trace incorporation of heavy water reveals slow and heterogeneous pathogen growth rates in cystic fibrosis sputum.

Authors:  Sebastian H Kopf; Alex L Sessions; Elise S Cowley; Carmen Reyes; Lindsey Van Sambeek; Yang Hu; Victoria J Orphan; Roberta Kato; Dianne K Newman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-29       Impact factor: 11.205

4.  Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.

Authors:  Daniel J Wolter; Julia C Emerson; Sharon McNamara; Anne M Buccat; Xuan Qin; Elizabeth Cochrane; Laura S Houston; Geraint B Rogers; Peter Marsh; Karandeep Prehar; Christopher E Pope; Marcella Blackledge; Eric Déziel; Kenneth D Bruce; Bonnie W Ramsey; Ronald L Gibson; Jane L Burns; Lucas R Hoffman
Journal:  Clin Infect Dis       Date:  2013-04-26       Impact factor: 9.079

Review 5.  Microbial uptake by the respiratory epithelium: outcomes for host and pathogen.

Authors:  Margherita Bertuzzi; Gemma E Hayes; Elaine M Bignell
Journal:  FEMS Microbiol Rev       Date:  2019-03-01       Impact factor: 16.408

6.  Prolonged growth of a clinical Staphylococcus aureus strain selects for a stable small-colony-variant cell type.

Authors:  Long M G Bui; Peter Hoffmann; John D Turnidge; Peter S Zilm; Stephen P Kidd
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

Review 7.  Host-pathogen interplay in the respiratory environment of cystic fibrosis.

Authors:  Lael M Yonker; Cristina Cigana; Bryan P Hurley; Alessandra Bragonzi
Journal:  J Cyst Fibros       Date:  2015-03-19       Impact factor: 5.482

Review 8.  Impact of nasopharyngeal microbiota on the development of respiratory tract diseases.

Authors:  S Esposito; N Principi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-09       Impact factor: 3.267

9.  Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa.

Authors:  Wibke Katharina Janhsen; Christin Arnold; Julia Hentschel; Thomas Lehmann; Wolfgang Pfister; Michael Baier; Klas Böer; Kerstin Hünniger; Oliver Kurzai; Uta-Christina Hipler; Jochen Georg Mainz
Journal:  Med Microbiol Immunol       Date:  2016-07-04       Impact factor: 3.402

10.  Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient.

Authors:  Paul R McAdam; Anne Holmes; Kate E Templeton; J Ross Fitzgerald
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.